She has conducted mixed-method, social science research in multiple countries in sub-Saharan Africa, the Middle East, and South and Southeast Asia, primarily focusing on HIV prevention. She served as the behavioral PI of FEM-PrEP, a multi-site, phase III, placebo-controlled trial of emtricitabine/tenofovir disoproxil fumarate as pre-exposure prophylaxis (PrEP) for HIV prevention among women in sub-Saharan Africa. She has also served as the PI of NIH-funded research on PrEP and risk compensation among women in South Africa and Kenya and as a multiple-PI on NIH-funded research on informed consent in HIV-related clinical research. Dr. Corneli joined the SBS core in 2017 and is the director of the Biomedical Prevention scientific working group.